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Sir
A number of breast cancer patients have been treated worldwide
with high-dose chemotherapy (HDCT) with stem cell support
worldwide. The survival advantage of this aggressive approach is
controversial.
The treatment of breast cancer patients with relapse following
high-dose chemotherapy is a major challenge for the oncologist.
Response rates have been negligible with regimens containing
anthracyclines, alkylating agents and antimetabolites. We have
tested a combination of docetaxel plus virorelbine, two drugs that
are not commonly included in the induction or consolidation
phases of high-dose chemotherapy programs.
From January 1997 to April 2001, 30 consenting patients relap-
sing after HDCT have been treated with docetaxel 60 mg m
2 i.v. in
1 h plus vinorelbine 24 mg m
2, both given on day 1 of a 21-day
course, with standard premedication. Patients were monitored for
neurotoxicity every three courses with full neurological examina-
tion, electroneurography, electromiography and somatosensorial
evoked potentials. Median age was 48 years (range 33–66). All
patients had been previously treated with anthracyclines. Prior
treatment included HDCT with stem cell rescue in all patients
(given as adjuvant treatment in six patients and for metastases in
22).
When given as adjuvant treatment for high-risk stage II–III
breast cancer (six patients), HDCT consisted of cyclophospha-
mide, tiothepa, and carboplatin (CTCb) as previously
described (Antman et al, 1992). An antracycline-containing regi-
men (ﬂuorouracil, epirubicin and cyclophosphamide) (FEC-75)
had been given as induction prior to HDCT. In 24 patients
treated with HDCT for metastases, CTCb was combined with
high-dose paclitaxel (Mayordomo et al, 1997; In ˜iguez et al,
1998; Isla et al, 1998). Tamoxifen had been given, starting right
after HDCT, to 22 patients (73%). Median disease-free interval
from HDCT was 12 months (range: 3–47): 17 months for
adjuvant HDCT and 12 for those treated for metastases. Sites
of disease upon protocol entry included bone in 15 patients,
liver in 13, lung in eight, lymph nodes in six, skin and soft
tissue in four and bone marrow in one. Eighteen patients
had metastases to one organ, six to two and six to three or
more. Median performance status was one (range 0–2). All
patients were evaluable for response, measured with standard
criteria (Miller et al, 1981). There were four complete responses
(13.3%) and 14 partial responses (46.6%) for a response rate of
60%. Five patients (16.6%) had stable disease and seven
(23.3%) progressive disease. Response rates were not different
for patients pretreated with HDCT as adjuvant versus those
treated for metastases and for those receiving HDCT without
paclitaxel. With median follow-up of 30 months or to death,
time to progression in all patients is 7 months (range 1–
40+). Median survival is 12 months (range 1–40+). Seven
patients are currently alive. Toxicity was manageable. In 137
courses delivered (median six per patient, range 1 to 9), there
were the following grade 3–4 toxicities: alopecia (137 courses,
100%), neutropenia (nine courses, 6.5%), febrile neutropenia
(eight courses, 5.8%) and anemia (two courses, 1.4%). No cases
of grade 3–4 neurotoxicity were seen.
High-dose chemotherapy with alkylating agents and stem-cell
support is the most active treatment in patients with metastatic
breast cancer. However there is controversy on whether HDCT
has a survival advantage over conventional chemotherapy (Lotz
et al, 1999; Stadtmauer et al, 1999). One of the reasons for this
discrepancy may be the lack of active chemotherapy regimens after
progression to HDCT.
Most patients undergoing aggressive HDCT programs receive an
induction with conventional-dose anthracyclin containing
chemotherapy, followed by HDCT with two or three alkylating
agents. So it is not surprising that conventional chemotherapy with
anthracyclines or alkylators, including cisplatin for relapsed meta-
static breast cancer after HDCT yields poor response rates.
The emergence of novel active agents in breast cancer such as
taxanes and vinorelbine has changed the scenario for these patients
(in addition to challenging the whole concept of HDCT, unless
these agents can be incorporated into it and response rates and
survival with higher doses are proven to be superior to conven-
tional doses). Sola et al reported 68% responses with paclitaxel
in 28 relapsed patients (Sola et al, 1999). Sundaran et al reported
ﬁve responses in seven evaluable patients with capecitabine
(Sundaran et al, 2000).
Docetaxel plus vinorelbeine is a promising combination in this
heavily pretreated population with 60% responses, even in
patients pretreated with paclitaxel. Toxicity was surprisingly
acceptable and neurotoxicity was not a major clinical problem.
The short duration of responses is the major challenge. No
doubt, more active novel drugs are needed to improve or sustain
these responses, especially in patients with shorter disease-free
interval. *Correspondence: JI Mayordomo; E-mail: josemajordomo@hotmail.com
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